Skip to content
Niklas Norgren, VP and Managing director at UmanDiagnostics, with newly recruited Maria Hörnberg and Ronja Lindgren. With the autumn's new hires, the in vitro diagnostics company has gone from being a micro to a small business.
Niklas Norgren, VP and Managing director at UmanDiagnostics, with newly recruited Maria Hörnberg and Ronja Lindgren. With the autumn's new hires, the in vitro diagnostics company has gone from being a micro to a small business.

Press release -

UmanDiagnostics continues to expand with recruitment of two new members of staff

“We have grown from nine to eleven employees. It feels like a significant milestone for us to pass ten employees”, says Niklas Norgren, VP and Managing Director at UmanDiagnostics.

It was just a year ago that the in vitro diagnostics company expanded its premises at Tvistevägen 48 in Umeå by 180 square meters to a total of 630 square meters. This expansion provided the company with additional storage and packaging capabilities for its finished products, enabling it to meet increased market demand.

UmanDiagnostics has also grown its personnel with the appointment of Maria Hörnberg this autumn. Maria joined the company from InfiCure Bio as an Assay Development Scientist, while Ronja Lindgren was also hired as a Laboratory Engineer.

This means UmanDiagnostics now has eleven employees in total, which by definition means it has gone from being a micro business (up to 9 employees) to a small business (10-50 employees).

“Maria’s appointment strengthens our research and development department, while Ronja’s role means we have a greater opportunity to scale up further our production to meet customer demand for our products”, says Niklas Norgren.

UmanDiagnostics was founded in 2006 by Niklas Norgren and Torgny Stigbrand. The company specializes in nerve injury markers and the Neurofilament light protein (NFL), which makes it easier to find and diagnose neurological diseases such as Multiple Sclerosis, ALS, and Alzheimer's disease.

The company released a new product – NF-light™ Serum ELISA – two years ago that is predicted to revolutionize research within the field of neurological diseases.

“The fact the company is growing both in terms of larger premises and more members of staff is a clear indication the business is doing well. We see an increased need for our products, reflected in our sales and customer deliveries. We have now secured suitable premises where we can continue to grow”, concludes Niklas Norgren.

For more information, please contact:
Niklas Norgren, VP och Managing director
nnorgren@quanterix.com
+46-(0)90-777 880

Related links

Topics

Categories


Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Contacts

Tomas Ruuth

Tomas Ruuth

Press contact Head of PR & Communications PR & Communications 072-4024697 www.ubi.se

Related content

We grow ideas that can change the world

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Umeå Biotech Incubator
Umeå Biotech Incubator
Tvistevägen 48C
907 36 Umeå
Sweden
Visit our other newsrooms